Beyond the Dichotomy: When a Heart Attack and Broken Heart Syndrome Are One
Science rarely arrives as a single revelation. More often, it accumulates — in clinical observations that don't fit the textbook, in questions that outlast careers, and in the partnerships that make sustained thinking possible. The theory I want to describe here is the product of all three.
Vladimir Shlyakhover was once my student. He has long since become my colleague in science and my friend in life. We are both from Ukraine — he now lives in Israel, I in the United States. Between us we carry decades of clinical and research experience with the heart under stress. And together we have arrived at something we no longer call a hypothesis. We call it a theory — because the evidence, in our view, demands that elevation.
The Two Diagnoses That Should Not Be Separate
Cardiology has long maintained a clean boundary between two cardiac conditions.
Acute myocardial infarction (AMI) — the classic heart attack — is understood as the consequence of a blocked coronary artery: oxygen fails to reach the heart muscle, cells die, a scar forms. The ischemic paradigm. It is the foundation of every cardiology curriculum, every guideline, every acute cardiac care protocol.
Takotsubo syndrome (TTS) — also called stress cardiomyopathy or "broken heart syndrome" — is understood as something categorically different: a surge of catecholamines (the stress hormones epinephrine and norepinephrine), triggered by emotional or physical shock, that temporarily stuns the heart muscle in a characteristic pattern without necessarily blocking any artery. It is currently classified as a separate entity from AMI. The two diagnoses are treated as mutually exclusive.
We challenge this boundary directly — not to collapse the distinction between the two conditions, but to argue that in a substantial number of patients they are not alternatives. They are simultaneous. And their co-existence, unrecognized, leads to missed diagnoses, misattributed clinical findings, and patients whose full injury burden goes untreated.
The Core Insight: A Spectrum, Not a Binary
Our framework is called STAMI — Superimposed Takotsubo and Acute Myocardial Infarction.
The central insight begins with a physiological fact that is not in dispute: every heart attack triggers a massive catecholamine surge. Pain, hemodynamic compromise, and activation of the sympathoadrenal axis drive plasma epinephrine and norepinephrine to dramatic levels within minutes of infarct onset. Those catecholamines do not merely affect heart rate and blood pressure. They exert direct, potentially injurious effects on cardiac muscle cells throughout the entire myocardium — including regions remote from the blocked artery.
This means that in every AMI patient, a Takotsubo-like process is, to some degree, simultaneously underway. The question is not whether it is present, but how large it is — and whether the clinical picture it produces is visible against the background of the ischemic injury.
Pure AMI and pure TTS are not two diseases. They are the opposite poles of a single continuous spectrum. At one end, the ischemic component dominates completely and the catecholaminergic injury is subclinical, invisible on standard imaging. At the other end, the catecholamine surge overwhelms even a minor ischemic event, producing a clinical picture indistinguishable from "pure" Takotsubo — while the underlying infarct goes undetected. Between these extremes lies a vast, clinically heterogeneous middle ground that the current binary classification systematically fails to capture.
What the Spectrum Explains
This reframing resolves observations that have long puzzled clinicians without adequate explanation:
Wall motion abnormalities beyond the culprit territory. When a patient with an inferior infarction also shows apical dysfunction, this is currently attributed to "remote ischemia" or "stunned myocardium." The STAMI model identifies it for what it more likely is: catecholamine-mediated injury operating in myocardium outside the ischemic zone.
Hemodynamic instability disproportionate to infarct size. Some patients collapse in ways their coronary anatomy cannot explain. The catecholaminergic component — invisible on angiography — is contributing an independent injury burden that standard assessment does not measure.
Marked QT prolongation not typical of focal infarction. This electrocardiographic feature is characteristic of catecholamine excess. Its presence in AMI patients is a signal of the superimposed Takotsubo process.
The two injury processes are not merely additive. They are mutually amplifying: ischemia augments catecholamine release, and catecholamines exacerbate microvascular dysfunction in the ischemic zone, a positive feedback loop that may account for the severity of combined STAMI presentations.
Four Clinical Faces of the Spectrum
The STAMI framework predicts four archetypal clinical phenotypes, each representing a different balance between the ischemic and catecholaminergic components:
Phenotype A: Large infarct, minor Takotsubo component — the most common presentation, typical in younger men, where the catecholaminergic injury is subclinical and the case is classified as "pure" AMI.
Phenotype B: Large infarct with a large Takotsubo component — carrying the worst prognosis, highest risk of cardiogenic shock and arrhythmia, most common in older patients.
Phenotype C: Small infarct with a large Takotsubo component — seen in young women with spontaneous coronary artery dissection (SCAD), where the dominant apical ballooning picture conceals the underlying ischemic event.
Phenotype D: Small-to-medium infarct, large Takotsubo component — often in older patients with psychiatric comorbidity, where baseline sympathoadrenal dysregulation amplifies catecholamine release far beyond what the ischemic trigger alone would produce.
In each phenotype, what appears as a single diagnosis at the bedside conceals a combined pathophysiology operating at the tissue level.
Theory Built on Evidence
Vladimir and I are explicit about the status of this work. It is not a hypothesis in search of its first evidence. It is a theory constructed from the convergence of multiple independent lines of published evidence: case reports and case series of combined AMI-TTS presentations accumulated over two decades, pathophysiological research into catecholamine cardiotoxicity, inflammatory biology of myocardial repair, and our own prior clinical and experimental work — including research on the mechanisms of post-infarction cardiac rupture published nearly forty years ago.
What remains is prospective validation: dedicated cohort studies, systematic cardiac MRI imaging of remote myocardium in AMI patients, and biomarker work capable of distinguishing the catecholaminergic injury signature from the ischemic one. The conceptual framework is established. The tools largely exist. The question is whether cardiology is ready to stop asking "infarction or Takotsubo?" and begin asking instead: how much of each — and in which patient?
Where to Read the Full Theory
The complete scientific paper — "Beyond the AMI–Takotsubo Dichotomy: A Spectrum Model of Catecholamine-Mediated and Ischemic Myocardial Injury" — is available in full at:
It includes the full pathophysiological framework, the spectrum model figure, phenotype descriptions, therapeutic implications, and complete references.
If You Want to Understand AMI as It Really Is
The standard view of myocardial infarction — entrenched in textbooks and guidelines for generations — treats it as necrosis of cardiac tissue caused by ischemia. That understanding is not simply incomplete. It is, in a fundamental sense, wrong about the nature of the process itself.
In "The Science of Healing: Optimality and New Understanding of Myocardial Infarction," I propose that myocardial infarction is not primarily a story of cell death from blocked blood flow. It is a unique form of acute aseptic inflammation — a biological process with its own logic, its own trajectory of healing, and its own conditions for success or failure. This reframing is not semantic. It changes how we understand the onset and development of the disease, and it opens the door to treatment strategies that work with the body's natural healing mechanisms rather than against them.
The book moves through three sections: the history of research that gradually revealed the true nature of the infarct; the theory of uncomplicated and complicated healing, including why the classical concept of necrosis is no longer sufficient; and the broader clinical implications — among them the Principle of Disease Optimality, a framework for nature-aligned medical practice applicable far beyond cardiology.
If the STAMI spectrum model described in this article represents a new way of seeing the infarct in real time — as a dual-injury event unfolding at the bedside — then this book provides the deeper theoretical ground beneath it: a new way of understanding what the heart is actually doing when it heals, and what medicine must do to support that process rather than obstruct it.
"The Science of Healing: Optimality and New Understanding of Myocardial Infarction"
by Mykola Iabluchanskyi
Available as an audiobook:
https://play.google.com/store/audiobooks/details?id=AQAAAECa60KryM
Mykola Iabluchanskyi, MD, PhD, DMSc, Prof. (Yabluchansky)
Comments